AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$RXRX

HERSHBERG ROBERT sold $125K of RXRX

HERSHBERG ROBERT sold 25,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $5.00 ($0.12M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Oct 7, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Bearish
medium confidence
Mentioned
$RXRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

While the sale is small, it provides transparency and may cause short‑term price adjustments.

02

Market read

A modest insider sale with limited trading relevance; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential upcoming clinical data releases or partnership news could outweigh the impact of this modest insider sale.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales, often used for routine portfolio rebalancing.

Company-level read

Ticker impact

$RXRXBearishMedium confidence
Context

Director Robert Hershberg sold 25,000 shares for $125,000 via a 10b5-1 plan, reducing his stake to 162,156 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A small $125K sale by a director is disclosed via Form 4; while the amount is modest, it signals potential concern and can prompt short-term price dip.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine and unlikely to shift sector sentiment.

Regional

No regional effect; the filing pertains to a US‑listed company only.

Global

Limited global relevance; the transaction size is too small to affect broader markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • Company
    Recursion Pharmaceuticals, Inc.

    US biotech listed on NASDAQ under ticker RXRX.

  • Individual
    Robert Hershberg

    Director of Recursion Pharmaceuticals who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

OCT 3
$RXRXMedAI 8/10

Advanced AI And ML Will Transform Biotech Drug Discovery

Recursion Pharmaceuticals (RXRX) reported positive Phase 1b/2 data for REC-4881 in treating familial adenomatous polyposis, with 75% of patients showing polyp burden reduction. Analysts maintained a $7.00 price target, adjusting assumptions slightly. The company plans FDA discussions in 2026 and pipeline expansion, citing AI-driven drug discovery advancements.

simplywall.st2 min
SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min